Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression

Hillerod Hospital, Denmark

Status: Terminated

Conditions: Major Depression

Treatments: Drug: Pindolol and venlafaxin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00159146

version 5

Details and patient eligibility

About

This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.

Full description

Antidepressant therapy has a delayed onset of action of 4-6 weeks. Pindolol has in some studies shown an accelerating effect. In this study we investigate the effect of 20 mg of pindolol retarded formulation in combination with Venlafaxine compared to placebo Pindolol and Venlafaxine for a duration of 19 days.

Effect is measured by the Hamilton Depression rating Scale and the Preskorn Scale (self-rating).

Enrollment: 31 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Major depression

Exclusion criteria

• Allergy towards pindolol, venlafaxine or other tablet constituents
• Liver or kidney impairment
• Diabetics
• Age below 18 years
• Severe cardiac disease
• Asthma.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

31 participants in 2 patient groups, including a placebo group

A

Active Comparator group

Description:

Venlafaxine and pindolol

Treatment:

Drug: Pindolol and venlafaxin

B

Placebo Comparator group

Description:

Venlafaxin and placebo

Treatment:

Drug: Pindolol and venlafaxin